Holen Sie sich die Stockscreener-App
11.98
1.24%
-0.15
Handel nachbörslich:
12.10
0.12
+1.00%
Tenax Therapeutics Inc Aktie (TENX) Neueste Nachrichten
Tenax Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Amid Continued Clinical DevelopmentEarnings Call Q&A - Newser
Tenax Therapeutics (TENX) Faces Resistance Test After 1.86% Pullback From Recent HighsShared Trade Alerts - Newser
What's Driving Tenax Therapeutics' Recent Surge - Kavout
Millennium Group (TENX) reports 1,347,130 shared votes, 5.1% stake - Stock Titan
Tectonic Therapeutics: Currently In A Catalyst Vacuum (NASDAQ:TECX) - Seeking Alpha
Understanding Momentum Shifts in (TENX) - Stock Traders Daily
LifeSci Capital Maintains Tenax Therapeutics(TENX.US) With Buy Rating, Maintains Target Price $27 - Moomoo
[SCHEDULE 13G/A] TENAX THERAPEUTICS, INC. Amended Passive Investment Disclosure - Stock Titan
Stonepine holds 975,200 shares in Tenax Therapeutics (NASDAQ: TENX), 3.7% stake - Stock Titan
VHCP group discloses 9.99% stake in Tenax Therapeutics (NASDAQ: TENX) - Stock Titan
Point72 group discloses 533,965 shares in Tenax Therapeutics (NASDAQ: TENX) - Stock Titan
BVF affiliates hold warrants convertible into TENX shares (NASDAQ: TENX) constrained by 9.99% blocker - Stock Titan
Perceptive Advisors (NASDAQ: TENX) reports 1.45M-share position - Stock Titan
About Us - FinancialContent
Tenax Therapeutics (TENX) Stock: Consolidating at $$11.93 — Next Move Ahead 2026-05-15Insider Buying - Newser
Dellora holds ~394,665 shares in TENX (Nasdaq: TENX) per amended 13G/A - Stock Titan
RTW Investments (TENX) reports 9.99% stake in Tenax Therapeutics - Stock Titan
Tenax Therapeutics (TENX) Stalls at $$11.94 — Consolidation Phase 2026-05-14Growth Factor - Newser
Tenax Therapeutics (NASDAQ: TENX) awards CFO 10K shares and 450K options - Stock Titan
TENAX THERAPEUTICS (TENX) CFO files Form 3 showing zero Common Stock owned - Stock Titan
Phase 3 spending lifts Tenax (NASDAQ: TENX) Q1 loss but extends runway - Stock Titan
TradingKey - TradingKey
Tenax Therapeutics Announces Q1 2026 Results, Advances Phase 3 LEVEL Study for TNX-103 and Expands Leadership Team - Minichart
Tenax Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
A Look at Tenax Therapeutics (TENX) Valuation After Q1 2026: EPS - GuruFocus
Tenax Therapeutics (TENX) Shares Updates on TNX-103 Phase 3 Stud - GuruFocus
Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - Investing News Network
Tenax Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Tenax Therapeutics (NASDAQ:TENX) Q1 2026 Slightly Beats EPS, Gears Up for Pivotal Phase 3 Data in Q3 - ChartMill
Tenax Therapeutics (NASDAQ: TENX) boosts Phase 3 spend, extends cash runway - Stock Titan
TENAX THERAPEUTICS ($TENX) Releases Q1 2026 Earnings - Quiver Quantitative
Tenax Therapeutics: Q1 Earnings Snapshot - Barchart.com
Tenax Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
William Blair Maintains Tenax Therapeutics(TENX.US) With Buy Rating - Moomoo
Guggenheim Raises Price Target for TENX, Maintains Buy Rating | TENX Stock News - GuruFocus
Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Millennium-linked entities file 13G/A for Tenax Therapeutics (NASDAQ: TENX) reporting ~2% stakes - Stock Titan
Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 - Investing News Network
Tenax uses stock options to hire 4 staff in clinical and commercial roles - Stock Titan
Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update - Weekly Voice
Avoiding Lag: Real-Time Signals in (TENX) Movement - Stock Traders Daily
T. Rowe Price (TENX) reports 2.84M shares, 11.0% stake in Tenax - Stock Titan
T. Rowe Price (NASDAQ: TENX) holds 2.95M shares, 17.2% disclosed - Stock Titan
Tenax Therapeutics (TENX) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
TENX SEC FilingsTenax Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Tenax Therapeutics names Timothy Healey as chief commercial officer By Investing.com - Investing.com Australia
Invus affiliates disclose 2.1% stake in Tenax Therapeutics (TENX) - Stock Titan
Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer - Investing News Network
Tenax Therapeutics names Timothy Healey as chief commercial officer - Investing.com
Tenax brings in drug launch veteran Timothy Healey to prep TNX-103 - Stock Titan
Tenax Therapeutics, Inc. (NASDAQ:TENX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Tenax Therapeutics appoints Thomas Staab as chief financial officer - MSN
Tenax wins bullish view at Cantor ahead of pivotal readout - MSN
Tenax Therapeutics (NASDAQ:TENX) Is In A Good Position To Deliver On Growth Plans - Sahm
Discipline and Rules-Based Execution in TENX Response - Stock Traders Daily
How do interest rates affect Tenax Therapeutics (TENX) stock | Q4 2025: Profit Exceeds ViewsSpin Off - newser.com
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):